Advertisement
ATOS vs BSEM
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATOS is a StrongBuy and BSEM is a Buy.
ATOS's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for ATOS turned positive on October 02, 2026. Looking at past instances where ATOS's MACD turned positive, the stock continued to rise in 42 of 51 cases over the following month. The odds of a continued upward trend are 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 02, 2026. You may want to consider a long position or call options on ATOS as a result. In 67 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 74%.
ATOS moved above its 50-day moving average on October 13, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ATOS crossed bullishly above the 50-day moving average on October 14, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 71%.
Following a +16.32% 3-day Advance, the price is estimated to grow further. Considering data from situations where ATOS advanced for three days, in 180 of 231 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
ATOS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 10-day RSI Indicator for ATOS moved out of overbought territory on October 19, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In 28 of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 46 of 52 cases where ATOS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ATOS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for ATOS entered a downward trend on October 07, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 53 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 55 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.967) is normal, around the industry mean (2.973). P/E Ratio (-0.599) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. ATOS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ATOS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
ATOS | BSEM | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 16 | 73 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 55 Fair valued | 34 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 97 | |
SMR RATING 1..100 | 98 | 100 | |
PRICE GROWTH RATING 1..100 | 63 | 96 | |
P/E GROWTH RATING 1..100 | 53 | 98 | |
SEASONALITY SCORE 1..100 | 5 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BSEM's Valuation (34) in the null industry is in the same range as ATOS (55) in the Medical Specialties industry. This means that BSEM’s stock grew similarly to ATOS’s over the last 12 months.
BSEM's Profit vs Risk Rating (97) in the null industry is in the same range as ATOS (100) in the Medical Specialties industry. This means that BSEM’s stock grew similarly to ATOS’s over the last 12 months.
ATOS's SMR Rating (98) in the Medical Specialties industry is in the same range as BSEM (100) in the null industry. This means that ATOS’s stock grew similarly to BSEM’s over the last 12 months.
ATOS's Price Growth Rating (63) in the Medical Specialties industry is somewhat better than the same rating for BSEM (96) in the null industry. This means that ATOS’s stock grew somewhat faster than BSEM’s over the last 12 months.
ATOS's P/E Growth Rating (53) in the Medical Specialties industry is somewhat better than the same rating for BSEM (98) in the null industry. This means that ATOS’s stock grew somewhat faster than BSEM’s over the last 12 months.
| ATOS | |
|---|---|
| RSI ODDS (%) | 2 days ago 90% |
| Stochastic ODDS (%) | 2 days ago 88% |
| Momentum ODDS (%) | 2 days ago 74% |
| MACD ODDS (%) | 2 days ago 82% |
| TrendWeek ODDS (%) | 2 days ago 77% |
| TrendMonth ODDS (%) | 2 days ago 78% |
| Advances ODDS (%) | 10 days ago 78% |
| Declines ODDS (%) | 3 days ago 87% |
| BollingerBands ODDS (%) | 2 days ago 76% |
| Aroon ODDS (%) | 2 days ago 89% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ATOS’s FA Score shows that 0 FA rating(s) are green while BSEM’s FA Score has 0 green FA rating(s).
- ATOS’s FA Score: 0 green, 5 red.
- BSEM’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ATOS’s TA Score shows that 6 TA indicator(s) are bullish.
- ATOS’s TA Score: 6 bullish, 4 bearish.
Price Growth
ATOS (@Biotechnology) experienced а +2.64% price change this week, while BSEM (@Biotechnology) price change was -18.63% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +1.28%. For the same industry, the average monthly price growth was -16.27%, and the average quarterly price growth was -16.72%.
Reported Earning Dates
ATOS is expected to report earnings on Nov 11, 2026.
BSEM is expected to report earnings on Nov 12, 2026.
Industries' Descriptions
@Biotechnology (+1.28% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
BSEM and
Correlation & Price change
A.I.dvisor tells us that BSEM and EYPT have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BSEM and EYPT's prices will move in lockstep.
| Ticker / NAME | Correlation To BSEM | 1D Price Change % | ||
|---|---|---|---|---|
| BSEM | 100% | -1.19% | ||
| EYPT - BSEM | 24% Poorly correlated | -0.44% | ||
| SER - BSEM | 24% Poorly correlated | -0.56% | ||
| ATOS - BSEM | 22% Poorly correlated | +7.51% | ||
| NKTX - BSEM | 21% Poorly correlated | -0.57% | ||
| BMEA - BSEM | 21% Poorly correlated | -15.23% | ||
More | ||||